Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Pancreatic cancer: advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
Targeting KRAS in cancer
RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Abstract Background KRAS G12C is a mutation that occurs in approximately 3 to 4% of
patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has …
patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has …
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit
its function have been continuing for decades. The most successful of these has been the …
its function have been continuing for decades. The most successful of these has been the …
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Abstract Background Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was
designed to have high potency and selectivity. Methods In a phase 1 study, we evaluated …
designed to have high potency and selectivity. Methods In a phase 1 study, we evaluated …
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Abstract RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the
most frequently mutated genes in cancer, with common driver mutations occurring at codons …
most frequently mutated genes in cancer, with common driver mutations occurring at codons …
Exploring treatment options in cancer: tumor treatment strategies
Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …
burdened cancer patients with onerous physical and psychological challenges …
The current state of the art and future trends in RAS-targeted cancer therapies
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …
Molecular targeted therapy for anticancer treatment
HY Min, HY Lee - Experimental & Molecular Medicine, 2022 - nature.com
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …